Codexis Stock Forecast, Price & News

Codexis' stock was trading at $10.12 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CDXS stock has increased by 72.6% and is now trading at $17.47.
View which stocks have been most impacted by COVID-19.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Codexis or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Codexis a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Codexis wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Codexis is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Codexis.

Codexis, Inc. (NASDAQ:CDXS) released its quarterly earnings results on Thursday, November, 5th. The biotechnology company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.16) by $0.06. The biotechnology company had revenue of $18.39 million for the quarter, compared to the consensus estimate of $14.97 million. Codexis had a negative net margin of 31.08% and a negative return on equity of 21.25%.
View Codexis' earnings history.

3 brokers have issued 1-year price targets for Codexis' stock. Their forecasts range from $16.00 to $21.00. On average, they expect Codexis' share price to reach $18.50 in the next year. This suggests a possible upside of 5.9% from the stock's current price.
View analysts' price targets for Codexis.

Codexis saw a increase in short interest in November. As of November 15th, there was short interest totaling 4,770,000 shares, an increase of 10.7% from the October 31st total of 4,310,000 shares. Based on an average daily trading volume, of 303,100 shares, the days-to-cover ratio is presently 15.7 days. Currently, 8.5% of the company's stock are short sold.
View Codexis' Short Interest.

Some companies that are related to Codexis include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seagen (SGEN), Alexion Pharmaceuticals (ALXN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Novavax (NVAX) and Ionis Pharmaceuticals (IONS).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Micron Technology (MU), Canopy Growth (CGC), Enphase Energy (ENPH), Intellia Therapeutics (NTLA), NVIDIA (NVDA), OPKO Health (OPK) and Antares Pharma (ATRS).

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

Codexis' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.73%), Wells Fargo & Company MN (4.07%), William Blair Investment Management LLC (3.73%), Vivo Capital LLC (2.49%), ARK Investment Management LLC (2.39%) and State Street Corp (2.04%). Company insiders that own Codexis stock include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, Gordon Sangster, James Lalonde, John J Nicols, Patrick Y Yang and Thomas R Baruch.
View institutional ownership trends for Codexis.

CDXS stock was sold by a variety of institutional investors in the last quarter, including First Light Asset Management LLC, William Blair Investment Management LLC, Nikko Asset Management Americas Inc., Essex Investment Management Co. LLC, Natixis, Wells Fargo & Company MN, State Street Corp, and Aigen Investment Management LP. Company insiders that have sold Codexis company stock in the last year include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, and Thomas R Baruch.
View insider buying and selling activity for Codexis.

CDXS stock was acquired by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Trigran Investments Inc., BlackRock Inc., Roubaix Capital LLC, Skandinaviska Enskilda Banken AB publ, SG Americas Securities LLC, Morgan Stanley, and Arrowstreet Capital Limited Partnership. Company insiders that have bought Codexis stock in the last two years include John J Nicols, and Patrick Y Yang.
View insider buying and selling activity for Codexis.

Shares of CDXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CDXS stock can currently be purchased for approximately $17.47.

Codexis has a market capitalization of $1.04 billion and generates $68.46 million in revenue each year. The biotechnology company earns $-11,940,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Codexis employs 161 workers across the globe.

The official website for Codexis is www.codexis.com.

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The biotechnology company can be reached via phone at 650-421-8100 or via email at [email protected]